The potential implication of these data is that treatment with STEAP1-BBζ CAR T cell therapy and resultant loss of STEAP1 tumor antigen expression in prostate cancer may result in further immunotherapy resistance through impaired antigen processing and presentation. The gene discussed is STEAP1; the disease is prostate carcinoma.